Advertisement

Topics

Sankyo Company Limited Company Profile

02:59 EDT 24th September 2017 | BioPortfolio

Agriculture

Location

5-1Nihonbashi Hon-cho 3-chome Chuo-ku
Tokyo
Tokyo
103
Japan

Contact

Phone: 81 3 5255 7111
Fax: 81 3 5255 7047


News Articles [455 Associated News Articles listed on BioPortfolio]

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (F...

Daiichi Sankyo and MD Anderson Collaborate to Accelerate Development of Acute Myeloid Leukemia Therapies

HOUSTON and TOKYO and BASKING RIDGE, N.J., Sept. 14, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today a...

Daiichi Sankyo, SBP begin phase 1 trial of DS─1211 in hyealthy volunteers

Daiichi Sankyo Company, Limited and Sanford Burnham Prebys Medical Discovery Institute (SBP) announced the start of a phase 1, first─in─human clinical trial of DS─1211 in healthy volunteers. DS...

Daiichi Sankyo, Boston Pharmaceuticals sign deal for selective RET inhibitor for solid tumors

Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

Daiichi Sankyo begins phase 3 ENVISAGE─TAVI AF study of once─daily Lixiana to treat patients with AF undergoing TAVI

Daiichi Sankyo Company, Limited, announced that the first patient has been enrolled into the ENVISAGE─TAVI AF study. The multinational, randomized phase 3b study will evaluate a treatment regimen ba...

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in ...

Zymeworks:David Poon, Ph.D.Executive Director, External R&D and Alliances(604) 678-1388bd@zymeworks.comorInvestor Inquiries:David MatousekSenior Manager, Investor Relations & ...

MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments

The University of Texas MD Anderson Cancer Center and Daiichi Sankyo said today they plan to develop novel therapies for acute myeloid leukemia (AML) through a multi-year collaboration whose value was...

Daiichi Sankyo Terminates Development & Commercialization Agreement with Charleston Laboratories

NewsDaiichi Sankyo terminates development and commercialization agreement with Charleston Laboratories regarding hydrocodone products in the U.S., including CL-108.

Drugs and Medications [1306 Associated Drugs and Medications listed on BioPortfolio]

Ranitidine [WOCKHARDT LIMITED]

Ranitidine [WOCKHARDT LIMITED]

Drug Facts

Famotidine [WOCKHARDT LIMITED]

Famotidine Tablets, USP 20 mg

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Clinical Trials [77 Associated Clinical Trials listed on BioPortfolio]

BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Companies [1466 Associated Companies listed on BioPortfolio]

Sankyo Co., Ltd.

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eager...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

More Information about "Sankyo Company Limited" on BioPortfolio

We have published hundreds of Sankyo Company Limited news stories on BioPortfolio along with dozens of Sankyo Company Limited Clinical Trials and PubMed Articles about Sankyo Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sankyo Company Limited Companies in our database. You can also find out about relevant Sankyo Company Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record